Global Ophthalmic Drugs Market: Overview
Ophthalmic drugs is a growing market driven by rising prevalence of intraocular eye disorders mainly in elderly population like glaucoma, cataract, age-related macular degeneration, diabetic retinopathy, etc. Also, there is an increasing incidence of eye diseases globally such as dry eye, conjunctivitis, uveitis, and others, and the number of patients suffering from eye diseases is expected to grow exponentially during the forecast period. As a result of this increasing patient pool across the globe, major market players are increasing R&D investments to capture the significant commercial opportunity through innovations in treatment methods, and improvement in drug’s mechanism of action with novel biological agents.
The market overview section of the report comprises qualitative analysis of the overall ophthalmic drugs market considering the factors determining the market dynamics such as drivers, restraints and opportunities, along with Porter’s five force analysis and market attractiveness analysis. In addition, such as market opportunity analysis for the disease indications, therapeutic class, product type, and distribution channels, and key industry developments has also been provided. Key industry developments include the major events occurred in past decade and are expected to occur during the forecast period which are likely to affect the market dynamics. The company share analysis has also been provided for global glaucoma drug market. The pipeline analysis of major as well as emerging market players has been given in the market overview section, along with the product comparison matrix of the major market players. The report also consists of a section depicting the major causes of blindness globally, as well as by regions.
Global Ophthalmic Drugs Market: Segmentation
The global ophthalmic drugs market is segmented in terms of disease indication, therapeutic class, product type, and distribution channels. The disease indication segment is further classified into dry eye, glaucoma, infection/inflammation, retinal disorders, allergy, uveitis, and others. The retinal disorders segment is further classified into wet age-related macular degeneration, dry age-related macular degeneration, diabetic retinopathy, and others. Among the disease indication segment, the retinal disorders segment accounted for the largest share of the global ophthalmic drugs market in 2016, owing to factors like exponentially rising patient pool demanding long-term treatment. However, the dry eye segment is expected to grow at a high CAGR during the forecast period, due to changing environmental conditions, pollutions, etc.
In terms of therapeutic class, global ophthalmic drugs market is divided into anti-inflammatory drugs, anti-infective drugs, anti-glaucoma drugs, anti-allergy drugs, anti-VEGF agents, and others. The anti-inflammatory drugs segment is bi-furcated into nonsteroidal anti-inflammatory drugs, and steroids. The anti-infective drugs are further sub-segmented into anti-fungal drugs, anti-bacterial drugs, and others. The anti-glaucoma drugs segment is classified into alpha agonist, beta blockers, prostaglandin analogs, combined medication, and others. On the basis of product type, the market is segmented into prescription drugs and OTC drugs. Based on distribution channels, the global ophthalmic drugs market is segmented into hospital pharmacies, online pharmacies, and independent pharmacies & drug stores.
Geographically, the ophthalmic drugs market has been categorized into five regions namely: North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The market size and forecast for each region has been provided for the period 2015 to 2025, in terms of disease indication, therapeutic class, product type, and distribution channels, along with the CAGR (%) for the forecast period 2017 to 2025.
Global Ophthalmic Drugs Market: Competitive Analysis
The report also provides a section on the competitive landscape, wherein the market share analysis of leading players in the global ophthalmic drugs market, in terms of percentage share in 2016 has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and increase their market share. The report concludes with the profiles of major players in the global ophthalmic drugs market such as Aerie Pharmaceuticals, Inc., ALLERGAN, Valeant Pharmaceuticals International, Inc., Bayer AG, Genentech, Inc. (F. Hoffmann-La Roche Ltd.), Novartis AG , Pfizer Inc., Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., and Shire among others. The major market players are evaluated on various parameters such as company overview, financial overview, product portfolio, business strategies and recent developments.
Global Ophthalmic Drugs Market is segmented as follows:
Global Ophthalmic Drugs Market, by Disease Indication
Global Ophthalmic Drugs Market, by Therapeutic Class
Global Ophthalmic Drugs Market, by Product Type
Global Ophthalmic Drugs Market, by Distribution Channel
Global Ophthalmic Drugs Market, by Geography
MRRSE offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.Get A Free Custom Research Quote